Jefferies initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $200 price target The company currently markets three central nervous system products, with two more to follow ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ ... us at www.axsome.com and follow us on LinkedIn and X. Forward Looking Statements Certain matters discussed ...

Ratings for Axsome Therapeutics AXSM were provided by 31 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...

March 25 (Reuters) - Axsome Therapeutics' (AXSM.O), opens new tab experimental drug to treat attention deficit hyperactivity disorder (ADHD) helped improve symptoms of the developmental disorder ...

Axsome Therapeutics stock opened at $98.86 on Thursday. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13. The company has a quick ratio of 2.04, a current ratio of 2. ...

Axsome Therapeutics (NASDAQ:AXSM) announced Tuesday that solriamfetol, its experimental therapy for attention deficit hyperactivity disorder (ADHD), reached primary and secondary goals in a Phase ...

Analyst Price Forecast Suggests 82.49% Upside As of April 2, 2025, the average one-year price target for Axsome Therapeutics is $180.41/share. The forecasts range from a low of $149.48 to a high ...

Axsome Therapeutics (AXSM) shares soared 4.2% in the last trading session to close at $101.67. The move was backed by solid volume with far more shares changing hands than in a normal session.

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics ... visit us at and follow us on LinkedIn and X ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axsome Therapeutics. The Motley Fool has a disclosure policy.